Lyon, France, May 24, 2022 – 6:00 p.m. CEST – MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotechnology company pioneering the development of Microbiome Ecosystem Therapies dedicated to improving the survival of patients with today announces its first R&D Review (“R&D Day”) for analysts and investors which will take place virtually on Tuesday, June 7, 2022 from 4:00 p.m. CEST (10:00 a.m. EST) to 6:00 p.m. CEST (12:00 p.m. IS).
On this occasion, speakers from MaaT Pharma will discuss the potential of the microbiota to improve cancer treatments, as well as the most recent clinical results of MaaT013 and MaaT033. They will also present the Company’s proprietary technology platform, the new generation of MaaT03X products and the construction of the largest cGMP plant for manufacturing complete ecosystem therapies from the microbiota in Europe.